(NASDAQ: SLNO) Soleno Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Soleno Therapeutics's revenue in 2025 is $0.On average, 5 Wall Street analysts forecast SLNO's revenue for 2025 to be $1,829,889,340, with the lowest SLNO revenue forecast at $1,082,690,641, and the highest SLNO revenue forecast at $2,320,378,925. On average, 5 Wall Street analysts forecast SLNO's revenue for 2026 to be $10,971,265,157, with the lowest SLNO revenue forecast at $10,568,271,284, and the highest SLNO revenue forecast at $11,597,308,894.
In 2027, SLNO is forecast to generate $27,741,368,190 in revenue, with the lowest revenue forecast at $22,832,345,189 and the highest revenue forecast at $36,575,775,302.